Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Therapeutics: Director Gillian Cannon to resign from board effective October 10, 2025

Neutral Impact 2 of 5 leadership Written later

Corcept director Gillian Cannon, Ph.D., notified the board on October 6, 2025 that she will resign effective October 10, 2025, and she did not cite any disagreement with the company. She will continue as a consultant to the board under a Consulting Services Agreement through the 2026 stockholder meeting, with her outstanding stock options continuing to vest, so the change is limited in scope for shareholders.

Key points

  • Resignation from the board effective October 10, 2025; no disagreement with the company cited
  • Consulting Services Agreement runs from the effective date until the 2026 stockholder meeting
  • Cash fee of $5,708.33 per month under the consulting agreement
  • Previously awarded stock options continue to vest on their original schedules

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECOct 6, 2025, 4:36 PM ET
Accession number0001193125-25-231963

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.